NasdaqGS:CMPSBiotechs
COMPASS Pathways (CMPS) Stock Looks Stretched Following Its 214% One Year Run
COMPASS Pathways stock has delivered a very strong 214.4% gain over the past year, yet the valuation checks and current market multiples point to a more cautious picture rather than a clear bargain.
The 214.4% one year return highlights how quickly sentiment has shifted around COMPASS Pathways and raises the bar for what needs to go right from here for the stock to justify that move.
Heavy investment in late stage psilocybin therapy development can support long term revenue potential, while...